Quanterix Corporation (QTRX)
NASDAQ: QTRX · Real-Time Price · USD
5.17
-0.31 (-5.66%)
At close: Oct 29, 2025, 4:00 PM EDT
5.23
+0.06 (1.16%)
After-hours: Oct 29, 2025, 6:17 PM EDT
Quanterix Revenue
Quanterix had revenue of $24.48M in the quarter ending June 30, 2025, a decrease of -28.81%. This brings the company's revenue in the last twelve months to $125.78M, down -2.74% year-over-year. In the year 2024, Quanterix had annual revenue of $137.42M with 12.30% growth.
Revenue (ttm)
$125.78M
Revenue Growth
-2.74%
P/S Ratio
1.68
Revenue / Employee
$267,057
Employees
471
Market Cap
240.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 137.42M | 15.05M | 12.30% |
| Dec 31, 2023 | 122.37M | 16.85M | 15.96% |
| Dec 31, 2022 | 105.52M | -5.03M | -4.55% |
| Dec 31, 2021 | 110.56M | 24.18M | 27.99% |
| Dec 31, 2020 | 86.38M | 29.64M | 52.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
QTRX News
- 2 months ago - Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit - Business Wire
- 2 months ago - Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference - Business Wire
- 2 months ago - Quanterix Corporation (QTRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Quanterix Releases Financial Results for the Second Quarter of 2025 - Business Wire
- 3 months ago - Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
- 3 months ago - Quanterix Announces Cooperation Agreement with Kent Lake Capital - Business Wire
- 3 months ago - Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC - Business Wire
- 3 months ago - Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire